MedPath

Surgery for Vocal Cord Paralysis

Phase 3
Terminated
Conditions
Unilateral Vocal Cord Paralysis
Registration Number
NCT00064571
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Brief Summary

Unilateral vocal fold paralysis (UVFP) is caused by injury to the nerve to the affected vocal fold. The injury to the vocal fold makes the affected person's voice sound "breathy". Voice therapy is usually tried first, and, if unsuccessful, surgical treatment is considered. The standard surgical treatment is called vocal fold medialization and aims to bring the injured cord to the midline. An alternative surgical treatment, vocal fold reinnervation, aims to bring a new nerve supply to the injured vocal fold. The reinnervation operation, which has some potential advantages over the medialization operation also requires several months for final results to be gained. The goal of this multicenter, randomized clinical trial is to see which of the two surgical treatments produces a better outcome.

In order to participate in this study patients with UVFP must meet all entry criteria and must be released from voice therapy by a speech-language pathologist. Information collected for the study (pre-surgery, and at 6 and 12 months after surgery) includes voice recordings, movies made of vocal fold function, airflow and pressure measurements of the voicebox, and an outcomes questionnaire.

Detailed Description

Unilateral vocal fold paralysis (UVFP) is caused by injury to the recurrent laryngeal nerve. Patients with UVFP may have significant impairment of vocal fold function, including a breathy paralytic dysphonia. There are several available approaches for the treatment of this condition. Vocal fold medialization is currently used by most otolaryngologists and is probably the standard of care for treating UVFP. An alternative approach is laryngeal reinnervation, which has a number of potential advantages over medialization but which requires several months before a final result is achieved. The primary goal of this multicenter, randomized clinical trial is to determine which approach produces a better outcome.

Patients with UVFP meeting all inclusion criteria and released from therapy by a speech-language pathologist will be randomized into either the medialization arm or the reinnervation arm. The data collection protocol consists of voice recordings, aerodynamic measurements, electroglottography, videostroboscopy, and a clinical outcomes questionnaire collected pre-treatment and at 6 and 12 months post-treatment.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (12)

UC-Irvine Medical Center

🇺🇸

Irvine, California, United States

Washington University

🇺🇸

St. Louis, Missouri, United States

University of Wisconsin

🇺🇸

Madison, Wisconsin, United States

George Washington University

🇺🇸

Washington, District of Columbia, United States

University of Alabama-Birmingham

🇺🇸

Birmingham, Alabama, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

University of Oklahoma

🇺🇸

Oklahoma City, Oklahoma, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Thomas Jefferson University

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath